Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 206


Characteristics and Outcomes Reported by Patients With Primary Sclerosing Cholangitis Through an Online Registry.

Kuo A, Gomel R, Safer R, Lindor KD, Everson GT, Bowlus CL.

Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30409-9. doi: 10.1016/j.cgh.2018.04.047. [Epub ahead of print]


Co-existing Hepatitis C and Alcoholic Liver Disease: A Diminishing Indication for Liver Transplantation?

Wieland A, Everson GT.

Alcohol Alcohol. 2018 Mar 1;53(2):187-192. doi: 10.1093/alcalc/agx101.


Obituary: The Impact of Thomas Earl Starzl, MD, PhD.

Fung JJ, Everson GT, van Thiel D.

Gastroenterology. 2017 Jun;152(8):1805-1806. doi: 10.1053/j.gastro.2017.05.002. Epub 2017 May 4. No abstract available.


Sofosbuvir and velpatasvir for the treatment of hepatitis C.

Jackson WE, Everson GT.

Expert Rev Gastroenterol Hepatol. 2017 Jun;11(6):501-505. doi: 10.1080/17474124.2017.1326817. Epub 2017 May 11. Review.


Curing Chronic Hepatitis C: A Cost Comparison of the Combination Simeprevir Plus Sofosbuvir vs. Protease-Inhibitor-Based Triple Therapy.

Langness JA, Tabano D, Wieland A, Tise S, Pratt L, Harrington LA, Lin S, Ghuschcyan V, Nair KV, Everson GT.

Ann Hepatol. 2017 May - Jun;16(3):366-374. doi: 10.5604/16652681.1235479.


Optimizing hepatitis C virus treatment through pharmacist interventions: Identification and management of drug-drug interactions.

Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ.

World J Gastroenterol. 2017 Mar 7;23(9):1618-1626. doi: 10.3748/wjg.v23.i9.1618.


Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.

Afdhal N, Everson GT, Calleja JL, McCaughan GW, Bosch J, Brainard DM, McHutchison JG, De-Oertel S, An D, Charlton M, Reddy KR, Asselah T, Gane E, Curry MP, Forns X.

J Viral Hepat. 2017 Oct;24(10):823-831. doi: 10.1111/jvh.12706. Epub 2017 Apr 10.


All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.

Reddy KR, Lim JK, Kuo A, Di Bisceglie AM, Galati JS, Morelli G, Everson GT, Kwo PY, Brown RS Jr, Sulkowski MS, Akuschevich L, Lok AS, Pockros PJ, Vainorius M, Terrault NA, Nelson DR, Fried MW, Manns MP; HCV-TARGET Study Group.

Aliment Pharmacol Ther. 2017 Jan;45(1):115-126. doi: 10.1111/apt.13823. Epub 2016 Oct 28.


Waiting for "The Liver" - No Longer?

Everson GT.

J Hepatol. 2016 Sep;65(3):467-9. doi: 10.1016/j.jhep.2016.06.013. No abstract available.


On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.

Welzel TM, Reddy KR, Flamm SL, Denning J, Lin M, Hyland R, Pang PS, McHutchison JG, Charlton M, Everson GT, Zeuzem S, Afdhal N.

Antivir Ther. 2016;21(6):541-546. doi: 10.3851/IMP3037. Epub 2016 Feb 18.


Viral hepatitis: Drug-drug interactions in HCV treatment--the good, the bad and the ugly.

Langness JA, Everson GT.

Nat Rev Gastroenterol Hepatol. 2016 Apr;13(4):194-5. doi: 10.1038/nrgastro.2016.24. Epub 2016 Feb 17. No abstract available.


Consensus Interferon for Recurrent Hepatitis C Infection in Nonresponders to Peginterferon and Ribavirin After Liver Transplant.

Nordstrom EM, Biggins SW, Gralla J, Rosen HR, Everson GT, Burton JR Jr.

Exp Clin Transplant. 2015 Dec;13(6):543-9.


Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.

Everson GT, Towner WJ, Davis MN, Wyles DL, Nahass RG, Thuluvath PJ, Etzkorn K, Hinestrosa F, Tong M, Rabinovitz M, McNally J, Brainard DM, Han L, Doehle B, McHutchison JG, Morgan T, Chung RT, Tran TT.

Ann Intern Med. 2015 Dec 1;163(11):818-26. doi: 10.7326/M15-1000. Epub 2015 Nov 10.


HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape.

Reau N, Fried MW, Nelson DR, Brown RS Jr, Everson GT, Gordon SC, Jacobson IM, Lim JK, Pockros PJ, Reddy KR, Sherman KE.

Liver Int. 2016 Apr;36(4):488-502. doi: 10.1111/liv.12993. Epub 2015 Nov 22. Review.


Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.

Everson GT, Sims KD, Thuluvath PJ, Lawitz E, Hassanein T, Rodriguez-Torres M, Desta T, Hawkins T, Levin JM, Hinestrosa F, Rustgi V, Schwartz H, Younossi Z, Webster L, Gitlin N, Eley T, Huang SP, McPhee F, Grasela DM, Gardiner DF.

Liver Int. 2016 Feb;36(2):189-97. doi: 10.1111/liv.12964. Epub 2015 Dec 6.


Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.

Charlton M, Everson GT, Flamm SL, Kumar P, Landis C, Brown RS Jr, Fried MW, Terrault NA, O'Leary JG, Vargas HE, Kuo A, Schiff E, Sulkowski MS, Gilroy R, Watt KD, Brown K, Kwo P, Pungpapong S, Korenblat KM, Muir AJ, Teperman L, Fontana RJ, Denning J, Arterburn S, Dvory-Sobol H, Brandt-Sarif T, Pang PS, McHutchison JG, Reddy KR, Afdhal N; SOLAR-1 Investigators.

Gastroenterology. 2015 Sep;149(3):649-59. doi: 10.1053/j.gastro.2015.05.010. Epub 2015 May 15.


Post-transplant survival is improved for hepatitis C recipients who are RNA negative at time of liver transplantation.

Fortune BE, Martinez-Camacho A, Kreidler S, Gralla J, Everson GT.

Transpl Int. 2015 Aug;28(8):980-9. doi: 10.1111/tri.12568. Epub 2015 Apr 16.


PRO view: treat to prevent recurrence of HCV.

Everson GT.

Liver Int. 2015 Jan;35(1):5-6. No abstract available.


Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study.

Verna EC, Saxena V, Burton JR Jr, O'Leary JG, Dodge JL, Stravitz RT, Levitsky J, Trotter JF, Everson GT, Brown RS Jr, Terrault NA; CRUSH-C Consortium.

Transplantation. 2015 Aug;99(8):1644-51. doi: 10.1097/TP.0000000000000629.


Noninvasive assessment of liver function.

Helmke S, Colmenero J, Everson GT.

Curr Opin Gastroenterol. 2015 May;31(3):199-208. doi: 10.1097/MOG.0000000000000167. Review.

Supplemental Content

Loading ...
Support Center